Epilepsy

UCB, announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted marketing authorization for Briviact (brivaracetam) as monotherapy and adjunctive therapy in the treatment of partial onset seizures of epilepsy patients with or without secondary generalization in adult patients with epilepsy

Marinus Pharmaceuticals, Inc. announced topline results from the Phase III double-blind, randomized, placebo-controlled RAISE trial (NCT04391569) evaluating the safety and efficacy of intravenous (IV) ganaxolone for the treatment of refractory status epilepticus (RSE)  RSE, in which prolonged continuous or rapidly recurring seizures do not respond to first- and second-line therapy, is associated with significant morbidity and mortality

This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.

The guideline makes evidence-based recommendations covering all aspects of diagnosis and management of adults with epilepsy including a completely revised section on epilepsy and women’s health and new sections covering psychiatric comorbidity, sleep, and mortality (including sudden unexpected death in epilepsy).